Brief: Edap Announces Approval To Initiate Randomized Clinical Trial Evaluating Focal One® As A Potential Treatment For Rectal Deep Infiltrating Endometriosis
30/11/2022 21:05
Nov 30 (Reuters) - Edap Tms SA EDAP.O :
* EDAP ANNOUNCES APPROVAL TO INITIATE RANDOMIZED CLINICAL
TRIAL
EVALUATING FOCAL ONE® AS A POTENTIAL TREATMENT FOR RECTAL DEEP
INFILTRATING ENDOMETRIOSIS
* STUDY TO BEGIN ENROLLING PATIENTS IN Q2 2023
Source text for Eikon: ID:nGNXbYqGXy
Further company coverage: EDAP.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Edap Tms SA
See all newsEdap Tms SA reports results for the quarter ended June 30 - Earnings Summary
FocalTherics slides after $40 million share sale
Brief: Focaltherics™ Announces Pricing Of Public Offering Of American Depositary Shares
Brief: Focaltherics™ Announces Proposed Public Offering Of American Depositary Shares
Edap Tms SA expected to post a loss of 20 cents a share - Earnings Preview